Background: Psoriasis treatment involves topical medications, oral medications, phototherapy, and/or biologics. The treatments used depend on a myriad of factors that change over time. Objective: To characterise the frequency of and reasons for treatment changes in patients with moderate to severe psoriasis. Methods: A chart review examined treatment changes at 902 visits by 116 patients seen between January 1, 2010, and June 30, 2015, for moderate to severe psoriasis and the physicians' justifications for those changes. 'Treatment change' was defined as switching between, adding, or removing medication classes or switching within the oral or biologic class. Results: There were 221 visits with treatment changes identified, and a change occurred every 4.1 visits. On average, there were 1.2 treatment changes per year. Patients treated for at least 1 year averaged 1 treatment change every 16 months. The most common type of change was from one biologic to another biologic (24.9%), followed by adding a nonbiologic to a biologic (18.6%). The most common reason for switching was poor control or flare of psoriasis. Affordability was a more common problem for biologics than for nonbiologic treatments. Conclusions: Biologic treatment options provide a major improvement over older systemic treatments, but patients still undergo frequent treatment changes to help control their disease.
1
and is associated with significant comorbidities and early death. 2 Psoriasis treatment involves topical medications, oral medications, phototherapy, and/or biologics depending on the character of the psoriasis (type and extent of lesions) and a patient's experience with previous treatments. 3 The class of treatment chosen depends on a myriad of factors and changes often due to fluctuations in disease severity over time as well as the efficacy and safety limitations of current treatment options. 3 Fortunately, many new treatments for psoriasis are being developed. The advancement of highly targeted treatments has resulted in treatments with excellent safety profiles that are far more effective than past options.
Understanding why patients with psoriasis change treatment can help dermatologists understand and better address their treatment needs. Patient-reported survey data suggest that poor efficacy is a main contributor. 4 The most common reason for stopping oral systemic medications (methotrexate, cyclosporine, and acitretin) is adverse effects, and the most common reason for stopping biologic medications is loss of efficacy. [5] [6] [7] [8] Treatment changes can occur, and the most common reason for switching between biologic medications is treatment failure, followed by lack of efficacy. 9 Patients' perceptions are similar, with inadequate disease control and side effects being the most common selfreported reasons for stopping medications. 10 Preliminary data from a chart review found 61% of treatment changes in patients with moderate to severe psoriasis are due to inadequate control of the disease.
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Our primary hypothesis is that, despite the rich variety of medications available to treat psoriasis (including tumour necrosis factor [TNF] inhibitors and interleukin [IL]-12/23 blocker), there continues to be considerable unmet treatment needs, reflected in how often patients fail treatment and need to either change to a different treatment or have 1 or more additional drugs added to their existing treatment regimen. We tested this hypothesis by characterising experiences with treatment change at the patient level, describing why and how often physicians change patients' psoriasis treatment. The primary objective was to determine why treatments are changed in patients with moderate to severe psoriasis. Secondary objectives included determining the average number of treatment changes per visit and per year of treatment, number of products used per visit, and the medication classes involved in each treatment change.
Methods
A chart review was conducted on electronic records of patients with moderate to severe psoriasis (defined by charts that stated the patient had moderate to severe psoriasis, body surface area of 10% or more affected with psoriasis, or treatment with phototherapy or systemic medication) seen between January 1, 2010, and June 30, 2015. Psoriasis treatments were bucketed into the following medication classes: oral systemic nonbiologics other than apremilast (methotrexate, acitretin, cyclosporine, hydroxyurea), apremilast, phototherapy (UVB, psoralen and UVA [PUVA]), and biologics (etanercept, adalimumab, ustekinumab). In addition, patients had to have at least 1 treatment change. A 'treatment change' was defined by (1) switching between medication classes, (2) adding or removing a medication class, (3) switching medications within the oral systemic nonbiologic medication class (apremilast is a separate category), or (4) switching medications within the biologic medication class. Phototherapy was considered a medication. Changes only involving a change in topical treatment were not included.
The study was performed at the Wake Forest Baptist Medical Center Department of Dermatology (WFD). The local human subjects research committee approved the protocol. Patients with psoriasis were identified from the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes used for billing patient encounters. Variables collected included age, sex, race/ethnicity, comorbidities mentioned in the office notes that are relevant to psoriasis treatment decision making (including obesity, congestive heart failure, and hepatitis B and human immunodeficiency infection), the medication classes involved in each treatment change, and reason for treatment change. For each treatment change, the visit date, change recommended (the treatment the patient was on and the treatment to which the patient was switched), and reason noted by the physician for the change were recorded.
This was a descriptive study and included a planned review of up to 600 charts, with at least 20 patients switched from each of etanercept, adalimumab, and ustekinumab. Microsoft Excel (Microsoft, Redmond, Washington) was used to collate the captured data. The patient demographics and comorbidities were summarised. The averages of the following variables were calculated: duration of time since psoriasis diagnosis, duration of time treated for psoriasis (measured as the time from the initial visit at WFD to the last visit analysed), number of clinic visits over the study period, number of visits with treatment changes over the treatment period, number of treatment changes per visit (calculated by dividing the number of visits with treatment changes by the number of visits over the treatment period), number of treatment changes per year of treatment (calculated by the number of treatment changes divided by the duration of treatment, adjusted to yearly basis), and the mean number of treatments used per visit (calculated as total number of medications used divided by total number of visits). The reasons for change for each class of treatment and for individual agents within a class where appropriate were categorised.
Results
We assessed treatment changes in 116 patients who had a mean age of 53.7 years and were 56.9% female ( Table 1 ). The top 3 common comorbidities were smoking (12.9%), psoriatic arthritis (12.9%), and diabetes mellitus (6.9%).
Data were collected from 902 visits (mean 7.8 visits/ patient), and there were treatment changes at 221 of those visits, leading to a treatment change every 4.1 visits (Table 2) . Per year, patients had an average of 1.17 visits during which a treatment change occurred. Among patients treated for at least 1 year, there was a mean of 0.76 treatment changes per year of follow-up.
The most common type of treatment change was from a biologic to another biologic (55, 24.9%), followed by adding a combination (eg, adding a nonbiologic to biologic: 41, 18.6%), nonbiologic to nonbiologic treatment (40, 18.1%), nonbiologic to biologic treatment (30, 13.6%), and nonbiologic to no treatment (15, 6.5%) ( Table 3 ). There were 36 changes from etanercept, 47 from adalimumab, and 35 from ustekinumab, as well as 19 changes to etanercept, 31 to adalimumab, 32 to ustekinumab, 113 to nonbiologic treatment, and 3 to secukinumab, and there were no observations Adding combination: A patient was on a biologic medication and a nonbiologic was added. 'Combination' was defined as a patient being on at least 1 biologic and 1 nonbiologic. h Dropping combination: A patient was on a combination treatment and the nonbiologic treatment was discontinued, so the patient only remained on the biologic treatment. Dropping the biologic in this situation would be 'biologic to nonbiologic'. i Combination to none: A patient was on combination treatment and everything was discontinued. j Combination: A patient was on a combination treatment and a nonbiologic was added or replaced the original nonbiologic, but the patient remained on combination treatment before and after the treatment change.
of apremilast. For treatment changes that were from one biologic to another biologic, adalimumab was changed to ustekinumab 14 times and etanercept 3 times, ustekinumab was changed to adalimumab twice and etanercept twice, and etanercept was changed to ustekinumab 7 times and adalimumab 9 times. The most common reason for a treatment change overall was poor control or flare of psoriasis (n = 126) ( Table 4) . Other common reasons for treatment change included patient preference (n = 30), affordability (n = 25), side effects (n = 21), and well controlled (n = 19). Poor control of psoriasis was the most common reason for treatment change from both nonbiologic and biologic treatments. Affordability was a more common problem for biologic than for nonbiologic treatments. Flare-up/poorly controlled psoriasis was the most common reason for treatment changes from methotrexate (40.7%), etanercept (61.1%), adalimumab (73.0%), and ustekinumab (48.3%) ( Table 5 ). The second most common reason for treatment change was side effects for methotrexate and affordability for the 3 biologics examined here.
Discussion
Major advances have been made in the treatment of psoriasis in the past decade. The available systemic treatments are safer and more effective than the oral treatments available in the past. 7 With methotrexate and cyclosporine, control of disease, rather than clearing, was the usual treatment goal. 11 Moreover, rotational treatment 12,13 was a common paradigm to help minimise the long-term, cumulative toxicity of treatment. Biologic treatments provide an option without longterm, cumulative toxicity, allowing patients to stay on the treatment indefinitely.
14 Nevertheless, we found that even with the availability of biologic treatments like etanercept, adalimumab, and ustekinumab, there continues to be a need for frequent changes in patients' treatment regimens. These biologic treatments are less effective in clinical practice than they were in clinical trials. 15 In clinical practice, less than 50% of patients on biologics after 5 years remain in remission and require a switch. 8 Despite the overall good efficacy of biologic treatment, insufficient efficacy (the treatment did not The most common reason for treatment change for each drug class is bolded, and the second most common reason is italicized. a The total number is larger than the number of visits with treatment changes since some patients had 2 reasons listed for medication adjustments. b Other than apremilast. c Nonbiologic to nonbiologic (other than apremilast): A patient was on a nonbiologic and had a nonbiologic added to or replacing previous medications. Nonbiologic to biologic: A patient was on a nonbiologics and had a biologic added to or replacing previous medications. e Nonbiologic to none: A patient was on a nonbiologic and it was discontinued, leaving the patient on no treatment. f Biologic to nonbiologic (other than apremilast): A patient was on a biologic that was discontinued and the patient remained on only a nonbiologic. g Biologic to biologic: A patient was on a biologic that was discontinued and replaced with a different biologic. h Biologic to none: A patient was on at least a biologic and everything was discontinued. i Adding combination: A patient was on a biologic medication and a nonbiologic was added. 'Combination' was defined as a patient being on at least 1 biologic and 1 nonbiologic. j Dropping combination: A patient was on a combination treatment and the nonbiologic treatment was discontinued, so the patient only remained on the biologic treatment. Dropping the biologic in this situation would be 'biologic to nonbiologic'. k Combination to none: A patient was on combination treatment and everything was discontinued. l Combination: A patient was on a combination treatment and a nonbiologic was added or replaced the original nonbiologic, but the patient remained on combination treatment before and after the treatment change.
work initially) and treatment failure (a treatment that initially worked but stopped working) are still common, occurring in our population about once a year, roughly once in every 3 visits, a frequency consistent with previous reports of treatment discontinuation with biologic treatment. 16 If minor treatment changes had been included-our study did not count any treatment changes only involving a change in topical treatment-treatment changes would be even more common. However, including these would have obscured the desired results of observing reasons for treatment change in moderate to severe psoriasis. A majority of the changes would be from topical treatments, an initial and least invasive approach, thus lessening the ability to analyse the stronger medication classes.
While the introductions of etanercept, adalimumab, and ustekinumab were major steps forward in psoriasis management, unmet treatment needs remain, as demonstrated by the frequent changes in treatment that are still needed. Recent studies support changing the bar for what is considered success in psoriasis management; higher levels of clearing are associated with more improvement in patients' quality of life. 17 Development of another generation of biologics with greater efficacy, as evidenced by higher rates of 90% and 100% improvements in the Psoriasis Area and Severity Index (PASI90 and PASI100) in head-to-head clinical trials, may help address patients' needs.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a grant from Novartis. Dr. Steven R. Feldman has received consulting, speaking, and/or research support from Abbvie, Amgen, Celgene, Galderma, Janssen, Lilly, Merck, Mylan, Novartis, Pfizer, and Taro. Dr. Steven R. Feldman is the founder and holds stock in Causa Research. Yang Zhao, Yunfeng Li, and Vivian Herrera are employed by Novartis Pharmaceuticals Corporation. Jaclyn Smith, Brooke Wehausen, and Irma Richardson have no conflicts to disclose.
